Email: cspc@cspc.cn
News
April 11, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Next: JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us